mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization in children aged 6 months to 5 years
mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization in children aged 6 months to 5 years
Simple item page
Full item details
- dc.contributor.author
- Aglipay, Mary
- Maguire, Jonathon
- Swayze, Sarah
- Tuite, Ashleigh
- Mamdani, Muhammad
- Keown-Stoneman, Charles
- Birken, Catherine
- Kwong, Jeffrey C.
- dc.date.accessioned
- 2024-01-04T18:40:28Z
- dc.date.available
- 2024-01-04T18:40:28Z
- dc.date.issued
- 2023-06
- dc.description.abstract - en
- IMPORTANCE: Data on mRNA-1273 (Moderna) vaccine effectiveness in children aged 6 months to 5 years are limited. OBJECTIVE: To assess mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization among children aged 6 months to 5 years. DESIGN, SETTING, AND PARTICIPANTS: A test-negative study using linked health administrative data in Ontario, Canada. Participants included symptomatic children aged 6 months to 5 years who were tested by RT-PCR. EXPOSURES: mRNA-1273 vaccination. MAIN OUTCOMES AND MEASURES: Symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization. RESULTS: We included 3467 test-negative controls and 572 test-positive cases. Receipt of mRNA-1273 was associated with reduced symptomatic SARS-CoV-2 infection (VE=90%; 95%CI: 53, 99%) and COVID-19-related hospitalization (VE=82%; 95%CI: 4, 99%) ≥7 days after the second dose. CONCLUSIONS and RELEVANCE: Our findings suggest mRNA-1273 vaccine effectiveness is initially strong against symptomatic SARS-CoV-2 infection and hospitalization in children aged 6 months to 5 years. Further research is needed to understand long-term effectiveness and the need for booster doses
- dc.identifier.doi
- https://doi.org/10.1101/2023.06.27.23291933
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/1444
- dc.language.iso
- en
- dc.publisher
- BMJ
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- dc.subject - fr
- Santé
- dc.subject.en - en
- Health
- dc.subject.fr - fr
- Santé
- dc.title - en
- mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization in children aged 6 months to 5 years
- dc.type - en
- Submitted manuscript
- dc.type - fr
- Manuscrit soumis
- local.peerreview - en
- No
- local.peerreview - fr
- Non
Download(s)
Original bundle
1 - 1 of 1
Name: aglipay-mrna-vaccine-effectiveness-covid-hospitalization-children.full.pdf
Size: 474.95 KB
Format: PDF
Collection(s)